Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.



Triple-negative breast cancer (TNBC) tumor cells lack HR and HER2 receptors and limited treatment options are available1,2

  • TNBC accounts for up to 20% of all breast cancers1
    • Prevalence is higher in African American and Hispanic women1,3
  • There is no standard-of-care chemotherapy available for previously treated patients with metastatic TNBC2
    • Combining agents from different drug classes is a commonly employed treatment strategy1,2
    • While treatment response might be achieved using combination therapy, relapse occurs quickly2

Following first-line treatment for mTNBC, published response rates with subsequent treatments are poor2

There is a significant unmet need for effective treatment options for later-line metastatic TNBC1,2


TRODELVY (sacituzumab govitecan-hziy) is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

References: 1. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106-116. 2. André F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23 Suppl 6:vi46-vi51. 3. Breast Cancer Hormone Receptor Status. American Cancer Society website. Accessed September 10, 2018.